ev3 — Q1 2009 Earnings Presentation
13 slides from ev3's earnings presentation, Apr 28, 2009
Slide 1: Q1 '09 Highlights
Q1 '09 Highlights April 28, 2009
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "estimat
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation, including "non- GAAP net sales on a constant currency basis," "non-GAAP legacy peripheral vascular net sales," "non-GAAP net sales by geography on a constant currency basis," "non- GAAP adjusted net
Slide 4: Q1 '09 Financial Summary
Q1 '09 Financial Summary Net product sales of $100.4 million +6% vs. Q1 2008; +10% constant currency* Peripheral vascular sales, excluding atherectomy*, +16% vs. Q1 2008; +20% constant currency* Peripheral stents +17% vs. Q1 2008; +22% constant currency* Neurovascular sales +11% vs. Q1 2008; +18% co
Slide 5: Actual Results vs. Last Quarter & Year Ago
Actual Results vs. Last Quarter & Year Ago *Constant Currency; For reconciliations, see our website at www.ev3.net. **All quarters presented are adjusted for amortization and non-cash stock-based compensation. Q1 2009 is also adjusted for a non- cash FoxHollow lease reserve adjustment and a realized
Slide 6: Total Q1 '09 Product Revenue Growth of 10%*
Total Q1 '09 Product Revenue Growth of 10%* Q2 Q3 Q4 Q1 Q1 East 101.5 100 105.6 95.1 100.4 Total Worldwide Product Sales ($M) Q2 Q3 Q4 Q1 Q1 East 35.9 36.6 39.4 34.8 38.7 Total International ($M) +24%* Q2 Q3 Q4 Q1 Q1 East 70.8 66.9 68.1 64.1 66.2 Worldwide Peripheral Vascular ($M) +7%* Q2 Q3 Q4 Q1 Q
Slide 7: Third consecutive quarter of cash and cash equivalents growth
Q1 08 Q2 08 Q3 08 Q4 08 Q1 09 East 57 38.7 45.9 59.7 66.9 Third consecutive quarter of cash and cash equivalents growth Cash / Cash Equivalents Cash/cash equivalents increased $7.3M Q1 '09 vs Q4 '08 Inventory days down 29% in Q1 '09 vs Q1 '08 Total debt decreased to $8.3M 7
Slide 8: Financial Summary: Continuing to Improve Performance
Financial Summary: Continuing to Improve Performance Net Product Sales* $95,050 $101,509 $100,018 $105,656 $100,395 Gross Profit $67,639 $71,528 $68,747 $71,316 $69,407 Gross Margin 66.8% 66.4% 64.2% 67.2% 69.1% Net Loss $(9,770) $(27,422) $(7,310) $(291,120) $(1,809) Adjusted net EPS (loss) per dil
Slide 9: Guidance - As of April 28, 2009
Guidance - As of April 28, 2009 Expect Full-Year 2009 Positive GAAP EPS Revenues: Q2 2009: $102 to $106 million Full-Year 2009: $420 to $430 million Adjusted EPS (loss)1 per diluted share: Q2 2009: $0.06 to $0.091,2 Full-Year 2009: $0.40 to $0.451,2 Adjusted EPS (loss) guidance is based on weighted
Slide 10: Business Model Structure - Select P&L Information
2008 % of sales 2007 2009 Goal Business Model Structure - Select P&L Information Sales 100% 100% 100% Gross margin 66% 65% 70% Selling, general & administrative 55% 69% 49% Taxes 0.4% 0.3% 1% Research & development 12% 17% 12% Stock-based comp & amortization 11% 11% 9% Adjusted net income (loss)* 2.
Slide 11: Continue to Stay Focused on Pathway to Profitable Growth
Continue to Stay Focused on Pathway to Profitable Growth Long-term profitable revenue growth Improve cost structure Increase sales force productivity Grow international sales Clinical evidence New products 1 2 3 4 5
Slide 12: Why Invest in ev3
Why Invest in ev3 I N S U M M A R Y 12 Broadest product offering in $2B growing global market largest pure-play in endovascular market Clear roadmap for sustained, profitable growth improved costs, productivity, clinical evidence, new products Company focused to achieve future profitability "vital f
Slide 13: Q1 '09 Highlights
Q1 '09 Highlights April 28, 2009